Avanos Medical Inc

AVNS remains in a Stage 2 advancing trend with a bullish structural bias. A Devil’s Bargain continuation pattern suggests potential near-term upside extension, but current consolidation above flat EMAs and overbought RSI indicate a likely pause. Price is tightly tracking above the 9EMA and 20EMA, offering potential pullback entry zones. On balance, the medium-term bias is bullish, but execution should be deferred until a favorable pullback into support.

• ↑Specialty nutrition segment delivered 8% organic growth in 2025.
• ↑Nexus Medical integration adds ~$5M revenue targeting double-digit growth.
• ↓Tariffs impose ~$30M manufacturing costs in 2026, pressuring margins.